211 related articles for article (PubMed ID: 24654454)
1. Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.
Kataoka H; Mori T; Yamamoto T; Sawada M; Kuroboshi H; Tatsumi H; Iwasaku K; Kitawaki J
Eur J Gynaecol Oncol; 2014; 35(1):11-5. PubMed ID: 24654454
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
[TBL] [Abstract][Full Text] [Related]
3. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
4. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Mitsuhashi A; Kawasaki Y; Hori M; Fujiwara T; Hanaoka H; Shozu M
BMJ Open; 2020 Feb; 10(2):e035416. PubMed ID: 32114477
[TBL] [Abstract][Full Text] [Related]
5. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Ga H; Taguchi A; Honjoh H; Nishijima A; Eguchi S; Miyamoto Y; Sone K; Mori M; Osuga Y
Arch Gynecol Obstet; 2023 Nov; 308(5):1629-1634. PubMed ID: 37310452
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Tamauchi S; Kajiyama H; Utsumi F; Suzuki S; Niimi K; Sakata J; Mizuno M; Shibata K; Kikkawa F
J Obstet Gynaecol Res; 2018 Jan; 44(1):151-156. PubMed ID: 29121428
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
[No Abstract] [Full Text] [Related]
9. Oncologic, fertility, and obstetric outcomes with MPA therapy in women with endometrial cancer and atypical endometrial hyperplasia.
Takeda A; Yamamoto Y; Tamura K; Aoki H; Noguchi H; Minato S; Kamada S; Arakaki R; Kaji T; Iwasa T
J Obstet Gynaecol Res; 2024 Apr; 50(4):633-638. PubMed ID: 38154145
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
[No Abstract] [Full Text] [Related]
11. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
12. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
13. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
14. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients.
Mitsuhashi A; Habu Y; Kobayashi T; Kawarai Y; Ishikawa H; Usui H; Shozu M
J Gynecol Oncol; 2019 Nov; 30(6):e90. PubMed ID: 31576686
[TBL] [Abstract][Full Text] [Related]
16. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
17. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
18. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
[TBL] [Abstract][Full Text] [Related]
19. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
20. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial.
Yang BY; Gulinazi Y; Du Y; Ning CC; Cheng YL; Shan WW; Luo XZ; Zhang HW; Zhu Q; Ma FH; Liu J; Sun L; Yu M; Guan J; Chen XJ
BJOG; 2020 Jun; 127(7):848-857. PubMed ID: 31961463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
